AbbVie Forecast, price target & analysts
AbbVie Target price 2026 - Analyst rating & recommendation
AbbVie Classifications & Recommendation:
AbbVie Price Target
| Target Price | $248.88 |
| Price | $229.31 |
| Potential |
8.53%
register free of charge
|
| Number of Estimates | 31 |
|
31 Analysts have issued a price target AbbVie 2027 .
The average AbbVie target price is $248.88.
This is
8.53%
register free of charge
$303.45
32.33%
register free of charge
$189.52
17.35%
register free of charge
|
|
| A rating was issued by 38 analysts: 26 Analysts recommend AbbVie to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbbVie stock has an average upside potential 2027 of
8.53%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 56.33 | 62.18 |
| 3.71% | 10.38% | |
| EBITDA Margin | 44.17% | 42.15% |
| 4.98% | 4.57% | |
| Net Margin | 7.52% | 30.86% |
| 15.22% | 310.21% |
31 Analysts have issued a sales forecast AbbVie 2025 . The average AbbVie sales estimate is
This results in the following potential growth metrics:
19 Analysts have issued an AbbVie EBITDA forecast 2025. The average AbbVie EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
33 AbbVie Analysts have issued a net profit forecast 2025. The average AbbVie net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.39 | 10.86 |
| 12.13% | 354.39% | |
| P/E | 21.12 | |
| EV/Sales | 7.53 |
33 Analysts have issued a AbbVie forecast for earnings per share. The average AbbVie EPS is
This results in the following potential growth metrics and future valuations:
Current AbbVie Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| HSBC |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
HSBC:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Oct 20 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
